X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (505) 505
Publication (88) 88
Book Chapter (7) 7
Dissertation (5) 5
Government Document (3) 3
Conference Proceeding (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
her3 (442) 442
humans (311) 311
index medicus (289) 289
oncology (229) 229
female (180) 180
her2 (179) 179
cancer (134) 134
receptor, erbb-3 - metabolism (132) 132
animals (128) 128
egfr (120) 120
cell line, tumor (118) 118
breast cancer (117) 117
erbb3 (117) 117
skin and connective tissue diseases (106) 106
expression (95) 95
receptor, erbb-3 - genetics (94) 94
receptor, erbb-2 - metabolism (93) 93
mice (86) 86
middle aged (81) 81
breast-cancer (80) 80
therapy (79) 79
trastuzumab (77) 77
epidermal growth factor (76) 76
cell biology (75) 75
tumors (73) 73
growth-factor receptor (72) 72
male (71) 71
aged (70) 70
signal transduction (70) 70
article (65) 65
epidermal-growth-factor (65) 65
survival (64) 64
body regions (62) 62
tyrosine kinase (62) 62
prognosis (61) 61
immunohistochemistry (60) 60
kinases (59) 59
receptor, epidermal growth factor - metabolism (59) 59
activation (57) 57
analysis (57) 57
receptor, erbb-2 - genetics (57) 57
receptor, erbb-3 - antagonists & inhibitors (57) 57
metastasis (54) 54
proteins (54) 54
resistance (54) 54
adult (53) 53
phosphorylation (53) 53
biochemistry & molecular biology (52) 52
heregulin (51) 51
breast neoplasms - metabolism (50) 50
gene expression (49) 49
breast neoplasms - drug therapy (48) 48
monoclonal antibodies (48) 48
research (48) 48
signal transduction - drug effects (48) 48
breast neoplasms - pathology (47) 47
ligands (46) 46
xenograft model antitumor assays (46) 46
care and treatment (45) 45
breast neoplasms - genetics (44) 44
monoclonal-antibody (44) 44
growth (41) 41
mutation (39) 39
cell proliferation - drug effects (38) 38
antineoplastic agents - pharmacology (37) 37
cell proliferation (37) 37
lung-cancer (37) 37
medicine & public health (37) 37
gene expression regulation, neoplastic (36) 36
medicine, research & experimental (36) 36
receptor, erbb-3 - immunology (36) 36
chemotherapy (35) 35
mice, nude (35) 35
receptor (35) 35
receptor, epidermal growth factor - genetics (35) 35
aged, 80 and over (34) 34
antineoplastic agents - therapeutic use (33) 33
genetic aspects (33) 33
neoplasms (33) 33
her4 (32) 32
up-regulation (32) 32
cells (31) 31
gene amplification (31) 31
acquired-resistance (30) 30
antibody (30) 30
erbb-2 protein (30) 30
receptor, erbb-2 - antagonists & inhibitors (30) 30
apoptosis (29) 29
cancer research (29) 29
cancer therapies (29) 29
inhibition (29) 29
phosphatidylinositol 3-kinase (29) 29
proto-oncogene proteins c-akt - metabolism (29) 29
treatment outcome (29) 29
antibodies (28) 28
cetuximab (28) 28
neuregulin-1 - metabolism (28) 28
pharmacology & pharmacy (28) 28
quinazolines - pharmacology (28) 28
receptor, epidermal growth factor - antagonists & inhibitors (28) 28
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Oncologist, ISSN 1083-7159, 08/2019, Volume 24, Issue 8, pp. 1095 - 1102
Background Seribantumab (MM‐121) is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3/ErbB3) to block... 
Seribantumab | Antibody | Targeted therapy | Biomarkers | HER3/ErbB3 | Heregulin | Translational | ErbB3 | RECEPTOR | OVARIAN-CANCER | PLATINUM-RESISTANT | PACLITAXEL | CETUXIMAB | ONCOLOGY | PATRITUMAB | HER3
Journal Article
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, ISSN 1422-0067, 03/2019, Volume 20, Issue 5
Affibody-based imaging of HER3 is a promising approach for patient stratification. We investigated the influence of a hydrophilic HEHEHE-tag ((HE)(3)-tag) and... 
VISUALIZATION | TARGET | gallium-68 | BIOCHEMISTRY & MOLECULAR BIOLOGY | NOTA | NODAGA | molecular imaging | CHEMISTRY, MULTIDISCIPLINARY | HER3 EXPRESSION | BREAST-CANCER | PEPTIDES | DOTA | IMPROVES | affibody | PROTEINS | PET | HER3
Journal Article
CANCER CELL, ISSN 1535-6108, 01/2016, Volume 29, Issue 1, pp. 117 - 129
Antibody-drug conjugate (ADC) which delivers cytotoxic drugs specifically into targeted cells through internalization and lysosomal trafficking has emerged as... 
GROWTH-FACTOR RECEPTOR | ADVANCED BREAST-CANCER | INHIBITION | ONCOLOGY | DOWN-REGULATION | TYROSINE KINASES | MECHANISMS | COMBINATION | ENDOCYTOSIS | TRASTUZUMAB EMTANSINE T-DM1 | HER3 | CELL BIOLOGY
Journal Article
Journal Article
International Journal of Molecular Sciences, ISSN 1661-6596, 03/2019, Volume 20, Issue 5
Affibody-based imaging of HER3 is a promising approach for patient stratification. We investigated the influence of a hydrophilic HEHEHE-tag ((HE)₃-tag) and... 
Molecular imaging | Gallium-68 | Affibody | NOTA | NODAGA | PET | HER3
Journal Article
Frontiers in Oncology, ISSN 2234-943X, 2012, Volume 2, p. 62
HER2-positive breast cancer accounts for 20-30% of all breast cancers and has the second-poorest prognosis among breast cancer subtypes. The approval of... 
Herceptin | Targeted therapies | Breast cancer | HER2/ERBB2 | Trastuzumab | HER3 | trastuzumab | breast cancer | targeted therapies
Journal Article
eLife, ISSN 2050-084X, 05/2018, Volume 7
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 2015, Volume 75, Issue 4, pp. 837 - 850
Journal Article
Medical Molecular Morphology, ISSN 1860-1480, 6/2019, Volume 52, Issue 2, pp. 106 - 113
The development of trastuzumab has significantly improved the prognosis of HER2-positive breast cancer. However, disease recurs in some patients with... 
Pathology | Medicine & Public Health | Molecular Medicine | Breast cancer | Anatomy | HER2 | Trastuzumab | Phosphorylated HER3 | HER3 | Immunohistochemistry | Survival analysis | Medical prognosis | Standardization | Survival | Patients | ErbB-2 protein
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2018, Volume 36, Issue 5, pp. 848 - 859
Journal Article
by Fu, WY and Lei, CH and Yu, Y and Liu, SW and Li, T and Lin, FX and Fan, XY and Shen, YF and Ding, M and Tang, Y and Ye, XT and Yang, YJ and Hu, S
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 05/2019, Volume 25, Issue 9, pp. 2835 - 2847
Purpose: Both EGFR and PI3K-Akt signaling pathways have been used as therapeutically actionable targets, but resistance is frequently reported. In this report,... 
LUNG-CANCER | CETUXIMAB | MECHANISM | ONCOLOGY | ACQUIRED-RESISTANCE | NOTCH | ANTIBODY | EGFR | CANCER STEM-CELLS | NEGATIVE BREAST-CANCER | HER3
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 07/2019, Volume 60, Issue 7, pp. 902 - 909
PET imaging with radiolabeled drugs provides information on tumor uptake and dose-dependent target interaction to support selection of an optimal dose for... 
BREAST-CANCER | SURVIVAL | antibody | dose selection | target engagement | MONOCLONAL-ANTIBODIES | immuno-PET | EXPRESSION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | HER3
Journal Article
International Journal of Cancer, ISSN 0020-7136, 10/2019, Volume 145, Issue 7, pp. 1838 - 1851
Journal Article